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Key points 
- Polyphosphate significantly augments the plasminogen activator capacity of 
factor XIIa.  
- Platelet-bound fibrin acts as a reservoir for plasminogen, factor XII(a) and 
polyphosphate.   
Abstract 
Activated factor XII (FXIIa) has plasminogen activator capacity but its relative 
contribution to fibrinolysis is considered marginal compared to urokinase and tissue 
plasminogen activator.  Polyphosphate (polyP) is released from activated platelets 
and mediates FXII activation.  Here we investigate the contribution of polyP to the 
plasminogen activator function of αFXIIa.  We show that both polyP70, of the chain 
length found in platelets (60-100-mer) and platelet-derived polyP, significantly 
augment the plasminogen activation capacity of αFXIIa.  PolyP70 stimulated auto-
activation of FXII and subsequent plasminogen activation, indicating that once 
activated, αFXIIa remains bound to polyP70.  Indeed, complex formation between 
polyP70 and αFXIIa provides protection against autodegradation.  Plasminogen 
activation by βFXIIa was minimal and was not enhanced by polyP70; highlighting the 
importance of the anion binding site. PolyP70 did not modulate plasmin activity but 
stimulated activation of Glu- and Lys- forms of plasminogen by αFXIIa.  Accordingly, 
polyP70 was found to bind to FXII, αFXIIa and plasminogen, but not βFXIIa. Fibrin 
and polyP70 acted synergistically to enhance αFXIIa-mediated plasminogen 
activation.  The plasminogen activator activity of the αFXIIa-polyP70 complex was 
modulated by C1 inhibitor and histidine rich glycoprotein, but not plasminogen 
activator inhibitors (PAI-1 and PAI-2).  Platelet polyP and FXII were found to co-
localize on the activated platelet membrane in a fibrin-dependent manner and 
decorated fibrin strands extending from platelet aggregates.  We show that in the 
presence of platelet polyP and the downstream substrate fibrin, αFXIIa is a highly 
efficient and favorable plasminogen activator. Our data is the first to document a 
profibrinolytic function of platelet polyP. 
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Introduction 
The contact pathway is comprised of factor XII (FXII), prekallikrein (PK), factor XI 
(FXI) and a non-enzymatic cofactor, high molecular weight kininogen (HK).  
Reciprocal proteolytic activation of FXII and PK to their active forms, FXIIa and 
kallikrein respectively, occurs via interaction with a negatively charged surface and is 
enhanced by Zn2+.1-5  FXI and PK circulate in complex with HK,6,7 which assembles 
these proteases on the activating surface.  FXIIa can cleave FXI stimulating the 
intrinsic pathway and downstream generation of thrombin, leading to its classification 
as a coagulation factor.  However, FXIIa is reported to participate in multiple 
pathways including inflammation, complement and fibrinolysis.8  
The profibrinolytic effects of the contact pathway are multifaceted involving direct 
and indirect interactions.  Kallikrein liberates the vasoactive peptide bradykinin from 
HK which induces a host of vascular responses, including release of tissue 
plasminogen activator (tPA) from endothelial cells.9  Kallikrein also directly cleaves 
single-chain urokinase (scuPA)10,11 to active uPA.  FXII shows distinct homology to 
tPA and uPA12-14 and in accordance with this FXIIa exhibits plasminogen activator 
activity.  The kinetics of the reaction are considered unfavourable13,15 but it is present 
in plasma at four orders of magnitude higher concentrations compared to tPA and 
uPA.16,17  During evolution, redundancy has developed in the fibrinolytic system, 
underscored by the relatively mild abnormalities associated with deficiency in tPA or 
uPA, while the double knockout exhibits a more acute phenotype.18  Under certain 
circumstances or within specific milieus it is plausible that FXIIa contributes to 
plasmin generation to complement or compensate for tPA and uPA activity and may 
be potentially relevant in vivo.19   
Several natural surfaces facilitate FXII activation including polyphosphate 
(polyP),20,21 RNA,22 misfolded proteins23 and collagen.24  PolyP is an ancient 
biomolecule that is ubiquitous in nature25 it is highly anionic and consequently acts 
as a propitious surface for activation of the contact pathway.20,21  PolyP is localized 
in platelet dense granules26 and is secreted upon activation21 alongside ADP, 
serotonin, and metal ions, including Zn2+.  Platelet polyP is approximately 60-100 
mers21 which is significantly shorter than the long-chain polymers (1000-2000 mers) 
in bacteria.27  Polymer length is crucial to polyP’s biological activity with shorter 
chains showing reduced capacity to activate the contact pathway.28  PolyP also 
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interacts with fibrin(ogen) and accumulates in clots altering their structural properties 
and susceptibility to tPA-mediated fibrinolysis.29,30 The half-life of polyP in plasma is 
relatively short (1.5-2 h)20 but could be preserved within the microenvironment of the 
thrombus.   
The plasminogen activator function of FXIIa is augmented by artificial surfaces and 
Zn2+.31  Here, for the first time, we show that a natural surface, polyP, amplifies the 
plasminogen activator function of FXIIa.  Indeed polyP, of approximate chain length 
of that found in platelets, binds both FXII(a) and plasminogen, indicative of a 
template mechanism of activation.  Importantly, we also demonstrate that platelet-
associated fibrin acts as a reservoir for FXII(a), plasminogen and platelet-released 
polyP.    
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Methods 
Collection of blood and preparation of plasma & platelets 
For platelet experiments, peripheral blood was collected into acid citrate dextrose 
(ACD) solution A vacuettes (Greiner Bio-one LTD); the first 3 ml was discarded. 
Platelets were washed and counted as described.32  Pooled normal plasma (PNP) 
that is essentially free of platelets was prepared from whole blood of 20 normal 
donors collected into 3.2% trisodium citrate.33  
 
PolyP preparation 
PolyP was extracted from platelets as described.28 Experiments were performed with 
platelet-derived polyP, synthetic polyP65 (Sigma-Aldrich) or polyP70 (a kind gift from 
BK Giulini, GmbH).  Similar results were obtained with both synthetic preparations 
and for simplicity are described as polyP70 throughout and the concentration quoted 
as phosphate monomer (monomer formula, NaPO3). 
 
Clot lysis  
Plasminogen-depleted fibrinogen (3.8 µM), Glu- or Lys- plasminogen (0.24 µM) and 
αFXIIa (200 nM) were added ± polyP70 (70 µM) in 10 mM Tris-HCl [pH 7.4], 140 mM 
NaCl and 0.01% Tween20 to 96-well plates (Greiner).  Clotting was initiated with 0.25 
U/ml human thrombin and 10 mM CaCl2.  In an analogous set of experiments 200 
nM FXII was pre-incubated with polyP70 (140 µM) at ambient temperature for 30 min.  
In some cases tPA (1 pM) was also included. Some experiments incorporated the 
inhibitors PAI-1 (0.1-1 nM), PAI-2 (0.1-1 nM), C1 inhibitor (125-500 nM) or histidine-
rich glycoprotein (HRG; 0.25-1 µM).  PolyP70 was replaced by HeLa RNA (10 µg/ml) 
or equine type 1 (Horm) collagen (5 µg/ml) in some assays.  Absorbance at 405 nm 
was recorded every minute using a BioTek PowerWave plate reader and BioTek 
Gen5 software. 
 
Plasminogen activation assay 
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Plasminogen activation was analysed as described30 with the following modifications. 
αFXIIa (200 nM), Glu- or Lys- plasminogen (0-400 nM) and S2251 (0.5 mM) were 
added to microtiter plates in 10 mM Tris-HCl [pH 7.4], 140 mM NaCl and 0.01% 
Tween20 ± polyP70 (0-70 µM).  Alternatively, 200 nM FXII was added ± polyP70 (140 
µM).  Plasmin activity was detected by measuring the absorbance at 405 nm every 1 
min.  In a parallel set of assays the following inhibitors; PAI-1 (0.1-1 nM), PAI-2 (0.1-
1 nM), C1 inhibitor (125-500 nM) and HRG (0.25-1 µM) were incorporated.  In some 
experiments soluble fibrin (3.8 µM), prepared as described34 was coated onto plates 
overnight at 4°C before performing activity assays.  In some cases RNA (10 µg/ml) 
or collagen (5 µg/ml) were included in place of polyP70.   
 
FXIIa activity assay 
FXIIa activity was analysed as described,35 briefly αFXIIa (50 nM) and S2302 (0.25 
mM) ± polyP70 (70 µM) were added to microtiter plates and absorbance read at 405 
nm for 4 h, with addition of 5 μl (5 mM) S2302, or 5 μl (50 nM) protein at the 2 h mid-
point. 
 
Gels and binding assays 
In autodegradation experiments, αFXIIa (50 nM) was incubated ± polyP70 (1 µM) for 
up to 360 min before resolving on 4-12 % Bis-Tris gels (NuPAGE, Life Technologies) 
under non-reducing conditions and protein stained using InstantBlue™. 
PolyP70 was bound to Sepabeads as described36 and incubated with 5 µg of FXII, 
αFXIIa, βFXIIa or plasminogen. Flow through material and subsequent low salt (50 
mM NaCl) and high salt (1 M NaCl) washes were collected and fractions analysed by 
Western blotting as described37 using HRP-conjugated goat anti-human FXII (ERL) 
or HRP-conjugated goat anti-human plasminogen (ERL). 
 
Visualization of FXII and polyP on single platelets 
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Slides were coated with collagen (20 µg/ml) and thrombin (100 nM) and 
subsequently blocked with 5% bovine serum albumin.  Platelets (5 x 107/ml) were 
added to coated slides for 45 min with DAPI (25 µg/ml; Ex. 358, Em. 525), DyLight 
488 (Pierce, Thermo Scientific)-labelled human FXII (DL488-FXII; 365 nM; Ex. 493, 
Em. 518) and Alexafluor 647® conjugated annexin V (AF647-annexin V; 1/20, Life 
Technologies; Ex. 594, Em. 633) in the presence of CaCl2 (2 mM). In control 
experiments Benzonase nuclease (Sigma) was included during stimulation to 
degrade contaminating DNA and RNA.  Platelets were visualized by fluorescent 
confocal microscopy on a Zeiss LSM710 confocal microscope with 63x 1.40 oil 
immersion objective.  Images were recorded on bright field and on separate 
channels for each wavelength and analyzed using Zen 2012 software. 
 
FXII and platelet polyP distribution in plasma clots  
Washed platelets (6.35 x108/ml; final concentration in clot 1.5 x108/ml) were 
incubated with DAPI (20 µg/ml) and AF647-annexin V (1/20) before activating with 
collagen (100 µg/ml), TRAP-6 (100 µM) and CaCl2 (4 mM).  Activated platelets were 
added to PNP (50% final concentration) in the presence of DL488-FXII (365 nM) and 
DyLight 550 (DL550; Pierce, Thermo Scientific)-labelled human fibrinogen (120 nM; 
Ex. 562, Em. 576). Thrombin (24 nM) and CaCl2 (10 mM) were added and clots were 
allowed to form in Ibidi µ-slide VI0.4 ibiTreat chambers for 2 h.  Images were recorded 
as detailed above for single platelets. 
 
Flow Cytometry 
DL488-FXII (365 nM), and DAPI (10 µg/ml) were added to washed platelets (2 x 
107/ml) in Hepes resuspension buffer (pH 7.45) containing CaCl2 (2 mM) and 
stimulated with convulxin (CVX; 100 ng/ml) and TRAP-6 (20 µM) or CVX and 
thrombin (100 nM) for 45 min at ambient temperature. AF647-Annexin-V (1/20) was 
added 5 min before the end of stimulation.  In some cases 5 mM Gly-Pro-Arg-Pro 
(GPRP; Sigma-Aldrich,) was included to inhibit fibrin polymerisation. Analysis was 
performed on a Beckton Dickinson LSR II flow cytometer with FACSDiva 6.1.3 
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software (Beckton Dickinson) with appropriate compensation applied and 10000 
events collected per sample. Data were analysed using FlowJo V.X.0.6 software. 
Results are expressed as mean percent of positive platelets and median fluorescent 
intensity (MFI) ± SEM.  
 
Data analysis 
Data analysis was performed in GraphPad Prism® 5.04.  Clot lysis results are 
expressed as time to 50% lysis (CLT), derived from the time taken from the maximal 
amplitude of the clot to reach the midpoint to baseline.  Alternatively, graphs were 
normalised and data plotted as % turbidity. Plasmin generation was calculated as 
described38, briefly, absorbance at 405 nm was plotted against time-squared and the 
slope from the initial linear portion estimated. These values were used to calculate 
plasminogen activation rates using the specific activity of plasmin against S2251 that 
was experimentally determined to be 1.055 A405/min/µM (not shown).  Fold-changes 
in lysis were calculated from mean CLT data.  Statistical analysis was performed on 
CLT, plasmin activity assays and flow cytometry data using student’s t-test or when 
multiple parameters were tested one-way analysis of variance with Dunnett’s 
Multiple comparison post-hoc test.  P values of < 0.05 were considered significant. 
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 Results 
αFXIIa plasminogen activator activity is enhanced by polyP70 
Artificial surfaces can enhance the plasminogen activator capacity of αFXIIa.31  This 
prompted us to examine the effect of the ‘natural’ activator polyP, of approximate 
size (60-100-mers) of that found in platelets, in αFXIIa-mediated plasminogen 
activation.  In line with previous observations we show that αFXIIa is a relatively 
weak plasminogen activator.13,15  However, inclusion of polyP70 significantly 
augments the ability of αFXIIa to drive fibrinolysis, decreasing the CLT by 2.3-fold 
(105 ± 6 min vs. 238 ± 14 min; P<0.0001; Figure 1A).  Similarly, polyP70 accelerated 
αFXIIa-mediated plasmin generation (Figure 1B; P<0.0001) in a dose-dependent 
manner, with concentrations as low as 4.4 µM demonstrating a significant 
enhancement over αFXIIa alone (Figure 1C; P<0.0001). PolyP had no direct effect 
on the activity of preformed plasmin (Figure 1D; P=0.93).  This indicates that polyP70 
accelerates αFXIIa-mediated conversion of plasminogen to plasmin.  The derivative, 
βFXIIa, lacks the surface binding domain and is less efficient at stimulating 
plasminogen activation.16  The low level of plasmin generation observed with βFXIIa 
was not augmented by polyP70, reflecting the requirement of the anion binding 
domain of αFXIIa for interaction with polyP70 (Figure 1E; P=0.71).  Inclusion of Zn2+ 
in the reaction buffer did not further enhance the cofactor function of polyP70 in this 
reaction (not shown).  We found that platelet-derived polyP extracted from human 
platelets similarly enhanced the plasminogen activator capacity of αFXIIa (Figure 1 
F).    
As polyP is a known activator of FXII20,21,35 we examined its capacity to both 
stimulate FXII activation and subsequently stimulate its plasminogen activator 
function.  CLT were significantly longer with FXII (>300 min) compared to αFXIIa 
(238 ± 58 min) and similarly, rates of plasmin generation were significantly lower with 
FXII compared to αFXIIa, presumably reflecting the time for transition of zymogen to 
protease.  Nevertheless, polyP70 exhibits significant cofactor activity in clot lysis and 
activity assays when initiated with FXII-polyP rather than FXII alone (Figure 2A).  
We next investigated binding of polyP70 to FXII derivatives and found it complexed 
with FXII and αFXIIa, but not βFXIIa; confirming the critical role of the anion binding 
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site for this interaction (Figure 2B).  When in complex with polyP70 autodegradation 
of αFXIIa was delayed (Figure 2C).  The protective effect of polyP70 on αFXIIa was 
analysed using S2302 substrate (Figure 2D).  Addition of excess substrate to the 
αFXIIa reaction at 2 h generated a further increase in absorbance in the presence of 
polyP70 while no change was observed with αFXIIa alone.  No further increase in 
activity was observed when additional αFXIIa was added to reactions with polyP70 at 
2 h, confirming that protein is not limiting (not shown). We further analysed changes 
in αFXIIa activity in terms of cleavage of FXI, but were unable to detect any changes 
in FXI activation after 360 min incubation in the absence or presence of polyP70 (not 
shown). These data indicate that while polyP70 confers protection against 
autodegradation the differences may be too minor to alter functional activity toward 
physiological targets.       
 
αFXIIa enhances activation of Glu- and Lys- forms of plasminogen 
We found that plasminogen bound immobilized polyP70, and could be released by 
washing with high salt buffer (Figure 3A).  This is indicative of an electrostatic 
interaction with the polymer, as previously shown for other proteins.30,34,36  
Plasminogen circulates in two forms; the predominant Glu-plasminogen is described 
as the ‘closed’ conformation, while the truncated Lys-plasminogen, cleaved at the C-
terminus by plasmin, is in an ‘open’ conformation and exhibits a shorter half-life.  
Enhanced binding of Lys-plasminogen to fibrin39 and activators tPA and uPA results 
in more rapid plasmin generation40,41. We observed faster plasmin generation and 
clot lysis with Lys-plasminogen (catalytic efficiency (CE) = 257.5 ± 21.0 M-1s-1) than 
Glu-plasminogen (CE = 18.5 ± 4.2 M-1s-1) when activated with αFXIIa (note the 
different scales in Figure 3B-C).  PolyP70 significantly augmented αFXIIa-mediated 
activation of Glu-plasminogen (CE = 41.1 ± 6.0 M-1s-1)  and Lys-plasminogen (CE = 
629.5 ± 75.6 M-1s-1) (Figure 3B) and accelerated clot lysis with both forms by ~2.6-
fold (Figure 3C).  These data suggest that polyP does not impact on the transition of 
the closed (Glu) to open (Lys) conformation of plasminogen, but directly facilitates 
cleavage to plasmin.   
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PolyP70 and fibrin augment αFXIIa-mediated plasminogen activation  
We have previously shown that polyP binds to fibrin(ogen) and alters the structure of 
the fibrin network34 and therefore assessed the impact on αFXIIa-mediated-
plasminogen activation.  Fibrin significantly enhanced the plasminogen activator 
function of αFXIIa (Figure 4A) and when combined, fibrin and polyP70 acted in 
concert to further amplify αFXIIa-mediated plasminogen activation (Figure 4A; 
P<0.001).   
We analysed whether other natural surfaces that stimulate FXII activation, such as 
RNA22, and collagen24 modulated the plasminogen activator function of αFXIIa.  RNA 
slightly enhanced plasmin generation by αFXIIa (Figure 4B; P<0.001), but not to the 
same magnitude as polyP70, while collagen was unable to stimulate activation.  
However, neither collagen nor RNA was effective in shortening the CLT like polyP70 
(Figure 4C; P<0.001).   
We next addressed whether αFXIIa acted in concert with tPA to mediate fibrinolysis.  
Inclusion of αFXIIa with a concentration of tPA (15 pM) sufficient to induce clot lysis 
further shortened the CLT from 69 ± 8.6 min to 47 ± 2.7 min (P<0.01; CLT of αFXIIa 
alone >300 min).  We then performed assays at a suboptimal dose of tPA (1 pM) 
which alone were not sufficient to induce lysis (CLT>300 min).  Addition of αFXIIa to 
clots containing 1 pM tPA significantly shortened the CLT (180 ± 9.4 min), but not to 
the extent of polyP70 (106 ± 6.5 min P<0.0001; Figure 4D).  A marginal decrease in 
CLT was observed with both αFXIIa and t-PA in the presence of polyP70 (97 ± 1.4 
min; P<0.01).  Similarly, visualisation of lysis in real-time (Video 1) demonstrated 
significantly faster lysis in the presence of both αFXIIa and tPA compared to tPA 
alone.  Interestingly, the pattern of lysis in the presence of αFXIIa was different, with 
clots lysing from the edge inwards, rather than proceeding with a defined lysis front 
as observed with tPA alone. These data illustrate that fibrin degradation is enhanced 
in the presence of both tPA and αFXIIa, compared to either activator alone. 
 
C1 inhibitor and HRG regulate the plasminogen activator activity of αFXIIa 
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Inclusion of the plasminogen activator inhibitors, PAI-1 and PAI-2, at plasma 
concentrations did not impact αFXIIa-mediated lysis (Figure 5A) or plasmin 
generation (Figure 5B) in the absence (not shown) or presence of polyP70 (Figure 
5A).  In contrast, C1 inhibitor significantly attenuated αFXIIa-mediated clot lysis 
(Figure 5A; P<0.0001) and plasmin generation (Figure 5B; P<0.001) ± polyP70.  HRG 
was also effective in down-regulating CLT (Figure 5A; P<0.0001) and plasminogen 
activation (Figure 5B; P<0.001) by αFXIIa ± polyP70.  The inhibition of αFXIIa-
mediated plasminogen activation by α2AP could not be examined due to its dominant 
inhibition of plasmin, but we found no discernible effects on direct inhibition of αFXIIa 
± polyP70 using S2302 (not shown).   
 
FXII and polyP bind to the surface of stimulated platelets 
We examined the interaction of DL488-FXII with platelets by flow cytometry and 
found that binding to CVX/thrombin stimulated platelets was significantly augmented 
compared to unstimulated (62.6 ± 6.9% versus 22.4 ± 13.5%; P<0.0001; Figure 6A).  
Platelets stimulated with CVX/TRAP-6 displayed a reduced capacity to bind DL488-
FXII (44.7 ± 8.9%; P<0.01).  Inclusion of GPRP, to impede fibrin polymerisation, 
markedly decreased the percentage of CVX/thrombin stimulated platelets that bound 
DL488-FXII (33.4 ± 6.9%; P<0.0001).  Together these data suggest platelet-bound 
fibrin plays a crucial role in the association of FXII with the activated platelet surface.  
We found a significantly higher degree of positivity for platelet-derived polyP on the 
surface of CVX/thrombin compared to unstimulated (52 ± 2% versus 8.1 ± 4.0%; 
P<0.0001). Surface-bound polyP was slightly decreased when platelets were 
stimulated with CVX/TRAP-6 (37.1 ± 7.2%; P<0.01) and upon inclusion of GPRP 
(31.5 ± 12.1%; P<0.01) suggesting a role for platelet-bound fibrin in its retention on 
the activated platelet membrane (Figure 6B). 
Using fluorescence confocal microscopy we examined the localization of FXII on the 
activated platelet surface stimulated with CVX/thrombin.  Phosphatidylserine (PS)-
positive platelets bound DL488-FXII in a single protruding ‘cap’ on the platelet 
surface that is also rich in PS (Figure 6C and Video 2). DL488-FXII also bound to 
PS-negative, spread platelets in a central diffuse pattern over the area of the 
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granulomere (Figure 6D).  Staining for platelet-derived polyP was dispersed over the 
activated membrane of PS-positive platelets (Figure 6E).  Control experiments 
performed with nuclease, to degrade contaminating DNA and RNA, did not alter 
DAPI staining on activated platelets (Supplemental Figure S1).      
 
Platelet-derived polyP associates with the platelet surface in clots and co-localises 
with FXII on adjacent fibrin fibres  
The location of platelet-derived polyP and FXII was studied in plasma clots formed in 
the presence of activated platelets. Platelet-derived polyP associates with the 
surface of activated platelets, particularly procoagulant PS-positive platelets and on 
platelet-bound fibrin (Figure 6F.)  No DAPI staining was observed in clots formed in 
the absence of platelets (data not shown). DL488-FXII also decorated fibrin fibres 
extending from platelet aggregates in clear co-localization with platelet-derived 
polyP.     
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Discussion 
In the present study we reveal a cofactor function for platelet-derived polyP in 
modulating the plasminogen activator activity of αFXIIa.  Platelet-derived polyP co-
localised with αFXIIa on the fibrin matrix extending from platelet aggregates.  
Blocking fibrin polymerisation with GPRP reduced binding of FXII, highlighting its 
importance in accrual of FXII in platelet-rich areas. Our findings demonstrate that in 
the presence of platelet polyP, αFXIIa is an efficient plasminogen activator.  In 
addition we show that fibrin augments the plasminogen activator capacity of αFXIIa 
in a synergistic manner to polyP.  There have been several reports on modulation of 
fibrinolysis by polyP20,29,30 but to our knowledge this is the first study to document a 
profibrinolytic function of platelet-derived polyP. 
The plasminogen activator function of αFXIIa has been described previously15,16,31, 
but has been largely ignored due to unfavourable kinetics.  Despite displaying a 20-
fold lower catalytic efficacy for plasminogen than uPA the relative abundance of FXII 
(375 nM) in plasma implies it may be relevant as a plasminogen activator.17 
Nevertheless, studies on the role of αFXIIa as a direct plasminogen activator are 
limited.19,42,43  Here we demonstrate that polyP, of approximately the size found in 
platelets, and platelet-derived polyP, significantly augment αFXIIa-mediated plasmin 
generation.  PolyP accelerates αFXIIa-mediated activation of Glu- and Lys-
plasminogen to a similar degree indicating that it does not facilitate transition of the 
closed to open conformation and nor does it directly impact on plasmin activity.  We 
observed binding of polyP to FXII(a) and plasminogen indicating that the cofactor 
function of this polymer is potentially mediated via a template mechanism on direct 
conversion of plasminogen to plasmin (Figure 7).  PolyP also stimulates 
autoactivation of FXII to αFXIIa35 and indeed affords some protection against 
autodegradation.  This could be relevant in terms of time frame, as FXII may become 
activated during clot formation, however by interacting with platelet-derived polyP its 
activity may be protected allowing it to subsequently participate in clot degradation.  
Indeed a recent publication highlighted the dual role of FXII in supporting fibrin 
formation and degradation of the clot.44 It is interesting to speculate on the complex 
role of this enzyme in modulating both fibrin formation, via generation of thrombin, 
and fibrin degradation via plasmin.  Further work is necessary to define the 
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procoagulant and profibrinolytic properties of αFXIIa and the role of effector 
molecules, such as polyP, in these processes.  Indeed opposing functions of a 
haemostatic enzyme is not an uncommon phenomenon.  The central enzyme 
thrombin is a prime example as its activity can be directed from procoagulant to 
anticoagulant processes depending on the effector molecule bound to exosite I or 
exosite II of the protease.45   
Fibrin also amplifies αFXIIa-mediated plasminogen activation, with maximal 
stimulation observed when both fibrin and polyP are present; suggesting that these 
molecules act synergistically to drive this process.  PolyP has the capacity to bind to 
fibrin29,30 and FXII(a) but these observations indicate that their respective binding 
sites on FXII(a) must be distinct.  Fibrin is a well-established cofactor for tPA-
mediated plasminogen activation.  αFXIIa was able to act in conjunction with tPA to 
significantly accelerate fibrinolysis, suggesting that incorporation of these activators 
into the forming fibrin network may facilitate clot degradation, as depicted in the 
model shown in Figure 7.  Interestingly, other surfaces that promote FXII activation 
and procoagulant function, specifically collagen24 and RNA22, were not effective in 
promoting αFXIIa-mediated fibrinolysis.  This suggests that cofactors molecules may 
drive αFXIIa activity toward distinct downstream target substrates.   
Antifibrinolytic functions of polyP have been described in the past.20,29,30  The first of 
these relates to enhanced activation of thrombin activatable fibrinolysis inhibitor 
(TAFI), due to acceleration of thrombin generation in the presence of polyP.20  
Activated TAFI down-regulates fibrinolysis by removing C-terminal lysine residues on 
fibrin that are important for binding plasminogen and tPA.46 PolyP also exerts 
antifibrinolytic function by altering the structure of the forming fibrin network.29,30 Our 
recent work has shown that this arises from impaired fibrin polymerisation.47  The 
modifications to the fibrin architecture by polyP alter its capacity to bind tPA and 
plasminogen, particularly that of partially degraded fibrin, thereby reducing tPA 
mediated plasmin generation.30 The profibrinolytic capacity of polyP described here, 
in terms of augmenting αFXIIa-mediated plasminogen activation, is intriguing 
particularly in light of the fact that fibrin also plays a role in this process.  It seems 
that the functions of polyP are more diverse than first thought and that this polymer 
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may exert different levels of control over the haemostatic system depending on 
timing and perhaps local concentrations of available reactants. 
Interestingly, the plasminogen activator inhibitors, PAI-1 and PAI-2 were ineffective 
in modulating polyP-αFXIIa-mediated plasminogen activation and fibrinolysis while 
C1-inhibitor and HRG both effectively neutralised activity.  C1-inhibitor is the 
predominant inhibitor of the contact pathway and regulates tPA-mediated 
plasminogen activation in situations when tPA is in excess over PAI-1.48-50  
Interestingly C1-inhibitor has also been shown to bind to polyP.51  Recent data 
highlighted the important role of HRG in modulating FXIIa activity and function.52-54  
HRG binds to FXIIa with incredibly high affinity in the presence of Zn2+ ions52 and 
both are released from platelet α-granules upon activation.55,56  HRG also associates 
with DNA and RNA and attenuates nucleic acid-driven activation of FXII.53   Here we 
show for the first time that HRG dampens αFXIIa activity directed toward the 
fibrinolytic pathway, adding to the complexity of this unusual adapter protein in 
regulation of haemostatic pathways.       
To date the binding sites for αFXIIa on platelets have not been elucidated but unlike 
other coagulation factors it does not bind directly to PS-positive platelets via Gla 
domains.57  We have previously shown that FXII(a) binds to fibrin and is actively 
incorporated into clots58, and elegant flow studies confirmed that FXII(a) interacts 
with platelet-associated fibrin.57  We observed significantly more FXII on the surface 
of platelets activated with thrombin/CVX than TRAP-6/CVX.  Blocking fibrin 
polymerisation with GPRP during thrombin/CVX stimulation, but not TRAP-6/CVX 
stimulation, significantly reduced the amount of FXII associated with platelets.  
Together these data indicate that fibrin anchors FXII to the activated platelet 
membrane.  PS-positive platelets display a cap of FXII on the activated surface that 
we have recently shown to be rich in fibrin(ogen) and plasminogen.59   We also show 
that platelet-derived polyP is retained on the membrane of PS-positive platelets, but 
unlike FXII, fibrinogen and plasminogen, it is homogenously distributed.  Inhibition of 
fibrin polymerisation attenuates association of polyP with the platelet surface, 
consistent with its known affinity for fibrin30 but does not completely abrogate 
binding. This suggests the presence of a second, as yet unidentified mechanism, 
that mediates retention of polyP on activated platelets.  Nevertheless, we also show 
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that polyP can translocate from the ‘hot-spots’ of PS-positive platelets into the 
surrounding fibrin network.  FXII also decorates fibrin strands accentuating the 
importance of platelet-bound fibrin in localising FXII and plasminogen59 in the vicinity 
of activated platelets.  Release of polyP from stimulated platelets could stimulate 
activation of FXII on fibrin and enhance the plasminogen activator capacity of 
αFXIIa; in this sense fibrin will be acting as a surface for its own destruction, as it 
does in t-PA mediated plasminogen activation.   
Thrombi are composed of different regions, the inner ‘core’ and the outer ‘shell’ 
which differ in their levels of platelet activation, aggregation and packing.60 The ’core’ 
is comprised of tightly packed, degranulated platelets encased in fibrin.60 ADP 
released from dense granules regulates α-granule secretion61-63 forming dense 
regions that stabilise the platelet aggregate.64  Concomitant release of polyP with 
ADP from dense granules suggests it may be retained in these low solute transport 
areas.  α-granule release occurs at lower agonist concentrations than dense granule 
release65,66 suggesting platelets in the outer core and shell may release fibrinogen 
and bind fibrin prior to polyP secretion thereby providing an anchor to retain polyP in 
the locale of the activated platelet aggregates.  
Multiple questions remain over how the pleotropic effects of FXII(a) are mediated in 
biological systems.  Further investigations on the role of αFXIIa as a plasminogen 
activator in vivo are warranted, particularly in light of the current interest in FXII as an 
antithrombotic target.  It is plausible that different surfaces act as cofactors that direct 
the function of FXIIa to procoagulant and profibrinolytic pathways, analogous to 
mechanisms seen with other proteins in the haemostatic cascade. Platelet-bound 
fibrin acts as reservoir for polyP and αFXII(a) and within the thrombus 
microenvironment may preserve their functional activity. Clearly there is still much to 
be learnt about the mysterious FXII(a) and its contribution to various physiological 
processes.   
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Legends 
Figure 1: αFXIIa plasminogen activator activity is enhanced by polyP70. (A) 
Clots were formed with 3.8 µM fibrinogen, 0.24 µM Glu-plasminogen, 200 nM αFXIIa 
in the absence (grey line) and presence (black line) of 70 µM polyP70. Clotting was 
initiated with 0.25 U/ml thrombin and 10 mM CaCl2 and subsequent lysis monitored 
at 405 nm. Mean data ± SEM is expressed as % turbidity of n=5, P<0.0001. (B) 
Plasminogen activation was analysed by incubating 200 nM αFXIIa and 200 nM 
plasminogen in the absence (light grey line) or presence of 70 µM polyP70 (black 
line). Plasmin activity was detected using the chromogenic substrate S2251 at 405 
nm.  Data represent mean and SEM of n=3 P<0.0001. (C) αFXIIa-mediated 
plasminogen activation was analysed in the presence of various concentrations of 
polyP70 by incubating 200 nM αFXIIa and 200 nM plasminogen in the absence 
(dashed line) or presence of 70 µM polyP70; 35 µM polyP70; 17.5 µM polyP70; 4.4 µM 
polyP70. Plasmin activity was detected using the chromogenic substrate S2251 at 
405 nm.  Data represent mean ± SEM of n=3 P<0.0001. (D) Similarly, direct effects 
of polyP on pre-formed plasmin (6.25 nM) were analysed in the absence (grey line) 
and presence (black line) of 70 µM polyP70 with S2251. Data represent mean ± SEM 
of n=3, P=0.93. (E) Activation of plasminogen (200 nM) by βFXIIa (200 nM) was 
monitored in the absence (grey line) and presence (black line) of 70 µM polyP70 and 
detected using S2251.  Data represent mean ± SEM of n=4 P=0.71. (F) 
Plasminogen activation was analysed by incubating 200 nM αFXIIa, 200 nM 
plasminogen in the absence (light grey line) or presence of 70 µM platelet-derived 
polyP (dark grey line). Plasmin activity was detected using the chromogenic 
substrate S2251 at 405 nm.  Data represent mean and SEM of n=3 P<0.0001.  
Figure 2:  PolyP70 stimulates FXII activation and modulates its plasminogen 
activator function (A) PolyP induces autoactivation of FXII - Left panel - Clots were 
formed with 3.8 µM fibrinogen, 0.24 µM Glu-plasminogen and 200 nM FXII in the 
absence (grey line) or presence (black line) of 140 µM polyP70. Clotting was initiated 
with 0.25 U/ml thrombin and 10 mM CaCl2 and subsequent lysis monitored at 405 
nm. Mean data ± SEM are expressed as % turbidity n=3, P<0.0001. Right panel – 
FXII (200 nM) and Glu-plasminogen (200 nM) were incubated in the absence (grey 
line) or presence (black line) of 140 µM polyP70 and plasmin activity detected using 
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S2251.  Data represent mean ± SEM of n=3 P<0.0001. (B) PolyP binds to FXII and 
αFXII - FXII, αFXIIa or βFXIIa (5 µg) were run through columns containing 
Sepabeads coated with polyP70 before collecting the flow through fractions (FT), low 
(50 mM NaCl; LS) and high (1 M NaCl; HS1) salt washes and comparing with 
starting material (SM). Protein was detected by Western blotting with an antibody to 
FXII. Image is representative of 3 separate experiments. (C) PolyP protects αFXIIa 
from autodegradation - αFXIIa (5 µg) was incubated ± polyP70 (100 µg) before 
resolving on 4-12 % Bis-Tris gels under non-reducing conditions. Data shown are 
representative of 3 separate experiments. (D) PolyP preserves αFXIIa activity 
αFXIIa (50 nM) activity was analyzed using S2302 in the absence (grey line) or 
presence (black line) of 70 µM polyP70. After 2 h additional S2302 substrate was 
added to the reaction (arrow) and readings continued for a further 2 h. Data 
represent mean ± SEM of n=3.  
  
Figure 3: αFXIIa enhances activation of Glu- and Lys- forms of plasminogen. 
(A) Binding of polyP70 plasminogen was analysed by running Glu-plasminogen 
through columns containing Sepabeads coated with polyP70 before collecting the 
flow through fractions (FT), low (50 mM NaCl; LS) and high (1 M NaCl; HS1) salt 
washes and comparing with starting material (SM). Protein was detected by Western 
blotting with an antibody to plasminogen. Image is representative of 3 separate 
experiments. (B) The rate of plasmin generation by αFXIIa (200 nM) in the presence 
(black line) or absence (grey line) of polyP70 (70 µM) was quantified for Glu- (left; 
P<0.05) and Lys- (right; P<0.01) plasminogen. Data are expressed as mean ± SD, 
n=3. (C) Fibrin clots were formed with fibrinogen (3.8 µM), αFXIIa (200 nM) and Glu- 
(left) or Lys- (right) plasminogen, in the absence (grey line) or presence (black line) 
of polyP70 (70 µM). Clotting was initiated with thrombin (0.25 U/ml) and CaCl2 (10 
mM) and lysis monitored at 405 nm. Mean data ± SEM are expressed as % turbidity 
n=3, P<0.0001. Note the different scales on the Lys-plasminogen compared to Glu-
plasminogen due to the different rates of activation of the isoforms of plasminogen.  
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Figure 4: PolyP and fibrin augment αFXIIa-mediated plasminogen activation. 
(A)- Plasminogen activation was analysed by incubating 200 nM αFXIIa, and 200 nM 
Glu-plasminogen (dotted line) in the presence of either 3.8 µM soluble fibrin (light 
grey line), 70 µM polyP70 (dark grey line) or both soluble fibrin and polyP70 (black 
line). Plasmin activity was detected using the chromogenic substrate S2251 at 405 
nm.  Data represent mean ± SEM n=3, P<0.001 (B & C) The plasminogen activator 
function of αFXIIa (200 nM) was analysed in the presence of different surfaces 
including polyP70 (70 µM), RNA (10 µg/ml) or collagen (5 µg/ml).  (B) Plasmin 
activity, generated from 200 nM plasminogen, was detected using S2251. (C) 
Fibrinolysis was analysed by forming clots from fibrinogen (3.8 µM), αFXIIa (200 
nM), Glu-plasminogen (200 nM), thrombin (0.25 U/ml) and CaCl2 (10 mM).  Lysis 
was monitored at 405 nm and mean ± SEM are shown as the time from maximal 
absorbance of the clot to 50% lysis, n=3 *** P<0.001. (D) Fibrin clots were formed 
and monitored as described in (C) with 70 µM polyP70 (black line), 1 pM tPA (grey 
line) or both polyP70 and tPA (dark grey line). The clots formed with tPA (dashed line) 
and tPA + polyP (light grey line) were formed in the absence of αFXIIa.  Mean data ± 
SEM are expressed as % turbidity n=4, P<0.0001.  
 
Figure 5: C1 inhibitor and HRG regulate the plasminogen activator function of 
αFXIIa. The impact of inhibitors on αFXIIa-polyP70 plasminogen activator function 
was monitored in the absence (black line) or the presence (grey line) of PAI-1 (1 
nM), PAI-2 (1 nM), C1 inhibitor (500 nM) or HRG (1 µM) by absorbance based clot 
lysis (A) or plasminogen activation assay, where plasmin was detected by cleavage 
of S2251 (B).  For simplicity the controls in the absence of polyP70 are omitted, as no 
lysis was observed either in the absence or presence of the inhibitor. Data represent 
mean and SEM of n=3.  
 
Figure 6: FXII and PolyP bind to the surface of stimulated platelets. (A-B) 
Washed human platelets were incubated with DL488-labelled FXII and DAPI to 
detect platelet-derived polyP and were left unstimulated or stimulated with CVX (100 
ng/ml) and thrombin (100 nM) or TRAP-6 (20 µM) ± GPRP (5 mM) for 45 min at 
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ambient temperature before analysing DL488-FXII (top panel) and DAPI (bottom 
panel) positive cells by flow cytometry. ** P<0.01, **** P<0.0001 vs. unstimulated 
platelets. † P< .05, †† P<0.01, †††† P<0.0001 CVX/thrombin stimulated platelets vs 
CVX/thrombin + GPRP. (C-E) Washed platelets (5 x 107/ml) were activated with 20 
µg/ml collagen and 100 nM thrombin in the presence of DL488-FXII (green) and 
DAPI (blue - E) and stained using Alexa-fluor®647 Annexin-V to detect 
phosphatidylserine (red). Images represent 3D render of z-stacks. Scale bars 
represent 5 µm. Representative images of 3 separate experiments. (F) Platelets (1.5 
x108 platelets/ml final concentration) were activated with 100 µg/ml collagen and 100 
µM TRAP-6 in the presence of CaCl2 before adding to plasma clots (50%) in the 
presence of DL550-Fgn (120 nM; orange), DL488-FXII (365 nM; green), DAPI (20 
µg/ml; light grey) and AF647-annexin V (1/20; red). Thrombin (24 nM) and CaCl2 (10 
mM) were added and clots were allowed to form for 2 h.  The image is representative 
of 3 separate experiments and displays a 3D render of a z-stack. Scale bar 
represents 10 µm. Images in C-F were obtained using a Zeiss LSM710 confocal 
microscope with a 63 X 1.40 oil immersion objective and were analysed using Zen 
2012 software.  
 
Figure 7: Interaction of αFXII(a), plasminogen, polyP and fibrin 
This cartoon depicts the potential template interactions between αFXII(a), 
plasminogen and polyP on polymerized fibrin. Fibrin forms the initial network and 
acts as a template for both tPA and FXIIa-mediated fibrinolysis due to its capacity to 
bind FXII(a), polyP, plasminogen and tPA. PolyP binds to fibrin, αFXII(a) and 
plasminogen and potentially acts as an anchor to reinforce the association between 
these proteins. When αFXII(a) is bound to fibrin and polyP its activation and 
plasminogen-activator activity is enhanced, facilitating plasmin generation on fibrin 
and subsequent degradation of the network. The cofactor capacity of fibrin in the 
stimulation of tPA-mediated plasminogen activation is well documented. Binding of 
the polyP-FXII(a) complex may to further facilitate plasminogen activation on the 
fibrin surface to accelerate fibrinolysis.     
 
